双靶点嵌合抗原受体T细胞免疫疗法在血液肿瘤中的研究新进展

Research advances in dual targeting chimeric antigen receptor T cell immunotherapy in hematological malignancies

嵌合抗原受体T细胞(CAR-T)免疫疗法是通过基因重组技术改造患者或异体来源的T细胞,使其表达嵌合抗原受体(CAR),并输注入患者体内后,可特异性识别肿瘤细胞抗原,从而杀伤肿瘤细胞。然而由于部分肿瘤细胞存在抗原逃逸,或是肿瘤相关抗原(TAA)表达水平和分布均存在异质性,使CAR-T细胞功效降低,进而导致疾病复发。目前研究结果表明,双靶点CAR-T免疫疗法可以提高CAR-T免疫疗法的有效性。近年,CAR-T免疫疗法在血液肿瘤治疗领域中取得了显著疗效。笔者拟就双靶点CAR-T免疫疗法在血液肿瘤中的研究最新进展进行阐述,旨在为CAR-T免疫疗法的改进及发展提供新的思路,探索更优的CAR-T免疫疗法。

Chimeric antigen receptor T cell(CAR-T)immunotherapy transforms patient′s or allogeneic T cells through gene recombination technology to express chimeric antigen receptor(CAR),and specifically recognize tumor antigen after infusion,so as to kill tumor cells after infusing to patients.However,due to antigen escape in some tumor cells,or heterogeneity of tumor associated antigen(TAA)expression level and distribution,the efficacy of CAR-T cells is reduced,which leads to disease recurrence.Current research results show that dual targeting CAR-T immunotherapy can improve the effectiveness of CAR-T immunotherapy.In recent years,CAR-T immunotherapy has achieved remarkable curative effect in the field of hematological malignancies treatment.This article intends to expound the latest research progress of dual targeting CAR-T immunotherapy in hematological malignancies,in order to provide a new idea for improvement and development of CAR-T immunotherapy and explore a better CAR-T immunotherapy.